the elucidation of the mechanisms of hydroxychloroquine for skin lesions in connective tissue diseases

1.羟氯喹（HCQ）在日本不是批准的药物。我们进行了初步研究，日本难治性CLE病例谁是管理HCQ的皮肤病变的改善程度进行了评估。并对4家医院27例应用HCQ的患者进行了协作评价。我们在医学期刊上报道了结果。 2.几乎没有关于HCQ处理的动物实验的文章。本研究以SLE狼疮样皮损模型小鼠MRL/lpr小鼠为动物模型，观察HCQ对SLE狼疮样皮损的影响。我们在IID 2013中报告了结果。 3.本研究拟对BLM诱导的硬皮病小鼠进行HCQ给药研究。在本研究开始之前，为了研究该模型小鼠皮肤硬化的机制，我们使用该模型小鼠检查了UVA 1照射对皮肤硬化的影响。我们在ICCLE 2013中报告了结果。

1. Hydroxychloroquine (HCQ) is not an approved drug in Japan. We conducted the pilot study that Japanese refractory CLE cases who were administrated HCQ were evaluated about the degree of the improvement of the skin lesions. More, 27 patients who were administrated HCQ at 4 hospitals were also evaluated in cooperation. We reported the results in medical journals. 2. There are almost no articles about the experiments on animals which were treated with HCQ. We administrated HCQ to MRL/lpr mice, model mice for SLE with LE-like skin lesions, and examined its effects on LE-like lesions. We reported the results in IID 2013. 3. We planned the study that BLM-induced sclerotic skin mice were administrated HCQ. Before the start of this study, for the investigation of the mechanisms of the skin sclerosis in this model mice skin, we examined the effects of UVA1 irradiation for sclerotic skin using this model mice. We reports the results in ICCLE 2013.